Synced daily from ClinicalTrials.gov via AACT. Last sync: .
13 Carisbamate clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 10 indications (including Epilepsy, Complex Partial & Lennox Gastaut Syndrome) and 3,030 total planned enrollment. 5 Phase 3 Carisbamate trials and 4 Phase 2 are listed. 1 Carisbamate clinical trial is actively recruiting at 7 U.S. sites across 6 states. Most recent activity: NCT05219617 (Dec 2028).
Where to Participate: All Carisbamate Trial Sites in the U.S. (7 sites across 6 states)
Every actively recruiting Carisbamatetrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
An Open-Label Extension Study to Evaluate the Safety and Tolerability of RWJ 333369 as Adjunctive Therapy in Patients 16 Years and Older With Partial Onset Seizures.
Carisbamate Retention Study (CaReS): Comparative Study on the Long Term Effectiveness, Safety and Tolerability of Carisbamate Compared to Two Other Frequently Prescribed Anti-epileptic Drugs (AEDs) in Patients With Epilepsy.
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
NCT00563459terminatedCarisbamate Retention Study (CaReS): Comparative Study on the Long Term Effectiveness, Safety and Tolerability of Carisbamate Compared to Two Other Frequently Prescribed Anti-epileptic Drugs (AEDs) in Patients With Epilepsy.
All Carisbamate trials (13)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
An Open-Label Extension Study to Evaluate the Safety and Tolerability of RWJ 333369 as Adjunctive Therapy in Patients 16 Years and Older With Partial Onset Seizures.
Carisbamate Retention Study (CaReS): Comparative Study on the Long Term Effectiveness, Safety and Tolerability of Carisbamate Compared to Two Other Frequently Prescribed Anti-epileptic Drugs (AEDs) in Patients With Epilepsy.
13 Carisbamate clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants. 11 are marked completed.
Are Carisbamate clinical trials recruiting in 2026?
Yes — 1 Carisbamate trial is actively recruiting in 2026, with 7 U.S. sites across 6 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Carisbamate being studied for?
Carisbamate is being studied for Epilepsy, Complex Partial, Lennox Gastaut Syndrome, Epilepsy, Seizures, Focal Motor Epilepsy and 17 more. The trials are grouped by indication on this page.
What phase is Carisbamate in?
Carisbamate clinical trials span 5 Phase 3, 4 Phase 2, 3 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Carisbamate clinical trials?
The lead sponsor across the most Carisbamate trials is SK Life Science, Inc., with 1 additional lead sponsor listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Carisbamateas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.